Lakewood-Amedex Biotherapeutics, Inc. (LABT) Stock Analysis & Investment Frameworks

Lakewood-Amedex Biotherapeutics, Inc. (LABT) stock analysis on Invetso. Review Lakewood-Amedex Biotherapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Lakewood-Amedex Biotherapeutics, Inc. Company Overview

Lakewood-Amedex Biotherapeutics, Inc. Key Financial Metrics

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Lakewood-Amedex Biotherapeutics, Inc. Investment Frameworks

Invetso analyzes Lakewood-Amedex Biotherapeutics, Inc. (LABT) across the following frameworks:

Explore More LABT Research